Results 151 to 160 of about 313,407 (265)
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano +52 more
wiley +1 more source
Thrombotic thrombocytopenic purpura: a Trojan horse of acute leukemia?: a case report. [PDF]
Nassani BM +4 more
europepmc +1 more source
Acute leukemia of ambiguous lineage: the known and the uncertain. [PDF]
Sherban A, Wolach O.
europepmc +1 more source
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir +9 more
wiley +1 more source
Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study. [PDF]
Kang Y +9 more
europepmc +1 more source
ABSTRACT Fanconi Anemia (FA) is the most frequent inherited bone marrow failure syndrome. A role for the XRCC2 gene in FA was suspected in 2012 and confirmed in 2016, but only two affected individuals have been described thus far, and no long‐term follow‐up is available.
Sabina Cenciarelli +11 more
wiley +1 more source
The Impact of Bacterial Infections on Delayed Hematopoietic Recovery in Patients with Acute Leukemia After Induction and Consolidation Therapy. [PDF]
Gawronski K +6 more
europepmc +1 more source
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun +7 more
wiley +1 more source
Revuforj (revumenib): a novel menin inhibitor for relapsed or refractory acute leukemia. [PDF]
Imtiaz A, Nazeer A, Haider E, Imran SB.
europepmc +1 more source
ABSTRACT Heterozygous germline variants in CBL disrupt its function as a negative regulator of the Ras/MAPK pathway, classically predisposing to Juvenile myelomonocytic leukemia (JMML) and moyamoya. We describe two affected siblings carrying a paternally inherited CBL variant (c.1210 T> C, p.
Michal Bar‐Hakim +12 more
wiley +1 more source

